Novo Nordisk has opened a new modern insulin formulation and filling facility in Russia for the treatment of diabetes.
The facility, which opened on April 10, is located in Technopark Grabtsevo in the Kaluga region of the country.
Its production will cover Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market.
Lars Rebien Sørensen, CEO at Novo Nordisk, commented: “The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies.
“With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day.”
The new arm is Russia’s first greenfield facility for the manufacturing of modern insulin, with environmental targets for carbon dioxide emission, water consumption and use of energy having already been confirmed.
The construction of the new facility has so far created around 150 jobs.
Anatoly Artamonov, Russian governor for the Kaluga region, added: “I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia.”
Last month, the firm revealed plans to resubmit its FDA marketing applications for diabetes therapies Tresiba and Ryzodeg after being rejected two years ago, with the regulatory body beginning its revaluation last week.